Letter to the editor regarding "Cost-effectiveness of benralizumab versus mepolizumab and dupilumab in patients with severe uncontrolled eosinophilic asthma in Spain".

IF 1.7 4区医学 Q3 ALLERGY

Journal of Asthma Pub Date : 2025-02-01 Epub Date: 2024-09-21 DOI:10.1080/02770903.2024.2394145

Florence Joulain, Kinga Borsos, Wei-Han Cheng, Clara Engroba-Teijeiro, Zhixiao Wang

引用次数: 0

查看原文本刊更多论文

致编辑的信，内容涉及 "西班牙严重不受控制的嗜酸性粒细胞哮喘患者使用苯拉利珠单抗与美泊珠单抗和杜匹单抗的成本效益"。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Asthma 医学-过敏

CiteScore

4.00

自引率

5.30%

发文量

158

审稿时长

3-8 weeks

期刊介绍： Providing an authoritative open forum on asthma and related conditions, Journal of Asthma publishes clinical research around such topics as asthma management, critical and long-term care, preventative measures, environmental counselling, and patient education.